ReviewCellular and molecular neurobiology2026
Diagnostic and Prognostic Value of Epigenetic Markers in Neurological Diseases. A Narrative Review.
Review in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological disorders are a leading cause of disability and death, yet sensitive and specific biomarkers remain limited. Epigenetic modifications link genetic background with environmental influences and may improve diagnosis, prognosis, and treatment stratification. The study aimed to summarise the current knowledge on epigenetics in neurological diseases, primarily focusing on their diagnostic value. We performed a narrative review with elements of systematic methodology. PubMed was searched up to November 21, 2025, using broad neurology and epigenetics terms followed by disease-specific queries. Sixty-five original studies on epigenetic markers with diagnostic or prognostic utility in neurological diseases were included. Across neurological disorders, multiple disease-associated epigenetic signatures have been reported. In neurodegenerative diseases, deoxyribonucleic acid (DNA) methylation patterns, histone modifications, and non-coding ribonucleic acid (RNA) profiles discriminate patients from controls and correlate with disease stage and clinical outcomes. In multiple sclerosis, methylation changes in genes involved in disease pathogenesis and characteristic microRNAs may distinguish relapsing from progressive forms and relate to disability. In ischemic stroke and transient ischemic attack, epigenetic alterations in vascular, metabolic, circadian, and inflammatory pathways, together with non-coding RNAs and extracellular vesicle signatures, are associated with stroke risk, severity, and outcome. Evidence in epilepsy, migraine, myasthenia gravis, dystrophies, and leukodystrophies suggests additional disease-specific epigenetic candidates. Epigenetic biomarkers across DNA methylation, histone modifications, and non-coding RNAs hold substantial potential to enhance precision neurology, from early diagnosis to prognostic stratification and therapy guidance. However, current evidence is heterogeneous and often based on small cohorts and variable methodologies. Large, longitudinal studies with standardised protocols are required before routine clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.